Second, follow-up studies are needed to identify specific drugs targeting SPATS2L and reveal whether SPATS2L mediates AML chemotherapy resistance (such as Ara-c, IDA) and the in-depth drug resistance mechanism. Here, SPATS2L is linked to acute myeloid leukemia.